» Articles » PMID: 39452154

Role of T Lymphocytes in Glioma Immune Microenvironment: Two Sides of a Coin

Overview
Journal Biology (Basel)
Publisher MDPI
Specialty Biology
Date 2024 Oct 25
PMID 39452154
Authors
Affiliations
Soon will be listed here.
Abstract

Glioma is known for its immunosuppressive microenvironment, which makes it challenging to target through immunotherapies. Immune cells like macrophages, microglia, myeloid-derived suppressor cells, and T lymphocytes are known to infiltrate the glioma tumor microenvironment and regulate immune response distinctively. Among the variety of immune cells, T lymphocytes have highly complex and multifaceted roles in the glioma immune landscape. T lymphocytes, which include CD4 helper and CD8 cytotoxic T cells, are known for their pivotal roles in anti-tumor responses. However, these cells may behave differently in the highly dynamic glioma microenvironment, for example, via an immune invasion mechanism enforced by tumor cells. Therefore, T lymphocytes play dual roles in glioma immunity, firstly by their anti-tumor responses, and secondly by exploiting gliomas to promote immune invasion. As an immunosuppression strategy, glioma induces T-cell exhaustion and suppression of effector T cells by regulatory T cells (Tregs) or by altering their signaling pathways. Further, the expression of immune checkpoint inhibitors on the glioma cell surface leads to T cell anergy and dysfunction. Overall, this dynamic interplay between T lymphocytes and glioma is crucial for designing more effective immunotherapies. The current review provides detailed knowledge on the roles of T lymphocytes in the glioma immune microenvironment and helps to explore novel therapeutic approaches to reinvigorate T lymphocytes.

Citing Articles

Integrative Machine Learning of Glioma and Coronary Artery Disease Reveals Key Tumour Immunological Links.

He Y, You G, Zhou Y, Ai L, Liu W, Meng X J Cell Mol Med. 2025; 29(2):e70377.

PMID: 39868675 PMC: 11770474. DOI: 10.1111/jcmm.70377.


Revolutionizing Neuroimmunology: Unraveling Immune Dynamics and Therapeutic Innovations in CNS Disorders.

Toader C, Tataru C, Munteanu O, Covache-Busuioc R, Serban M, Ciurea A Int J Mol Sci. 2025; 25(24.

PMID: 39769374 PMC: 11728275. DOI: 10.3390/ijms252413614.

References
1.
Fares J, Davis Z, Rechberger J, Toll S, Schwartz J, Daniels D . Advances in NK cell therapy for brain tumors. NPJ Precis Oncol. 2023; 7(1):17. PMC: 9932101. DOI: 10.1038/s41698-023-00356-1. View

2.
Devaud C, Yong C, John L, Westwood J, Duong C, House C . Foxp3 expression in macrophages associated with RENCA tumors in mice. PLoS One. 2014; 9(9):e108670. PMC: 4180934. DOI: 10.1371/journal.pone.0108670. View

3.
Chen H, Li M, Guo Y, Zhong Y, He Z, Xu Y . Immune response in glioma's microenvironment. Innov Surg Sci. 2021; 5(3-4):20190001. PMC: 7810204. DOI: 10.1515/iss-2019-0001. View

4.
Aldoghachi A, Aldoghachi A, Breyne K, Ling K, Cheah P . Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme. Neuroscience. 2022; 491:240-270. DOI: 10.1016/j.neuroscience.2022.03.030. View

5.
Gonzalez-Tablas Pimenta M, Otero A, Arandia Guzman D, Pascual-Argente D, Ruiz Martin L, Sousa-Casasnovas P . Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome. Brain Pathol. 2020; 31(2):365-380. PMC: 8018082. DOI: 10.1111/bpa.12927. View